Compare AEG & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEG | ARWR |
|---|---|---|
| Founded | 1983 | 2003 |
| Country | Netherlands | United States |
| Employees | 15500 | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 10.1B |
| IPO Year | N/A | 2009 |
| Metric | AEG | ARWR |
|---|---|---|
| Price | $6.78 | $55.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | N/A | ★ $81.50 |
| AVG Volume (30 Days) | ★ 5.8M | 1.9M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 5.46% | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $175.15 | N/A |
| Revenue Next Year | $1.22 | N/A |
| P/E Ratio | ★ $7.91 | $249.84 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.42 | $10.66 |
| 52 Week High | $8.15 | $76.76 |
| Indicator | AEG | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 30.77 | 30.90 |
| Support Level | N/A | $36.34 |
| Resistance Level | $8.02 | $66.37 |
| Average True Range (ATR) | 0.15 | 3.12 |
| MACD | -0.05 | -0.84 |
| Stochastic Oscillator | 0.00 | 8.07 |
Aegon is a life insurance and long-term savings business listed in the Netherlands. It was listed on the Amsterdam Stock Exchange in the 1980s and now has mature operations in the United States, the United Kingdom, and four growth markets of Brazil, China, Portugal, and Spain. Over recent years, Aegon has been moving through an extensive transformation program where management has sought to divest noncore operations and improve the risk profile of the business. Financial assets are the parts of the company that are now being run off. Aegon is looking to cycle out of capital-consumptive and volatile earnings products and recycle funds into capital-light and more predictable strategic businesses.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.